Client News

Abivax Announces Closing of $747.5 Million Public Offering

Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine

100 Patients Already Enrolled: ARTCLINE Reports Rapid Progress in Multicenter Clinical Study on Immune Support in Septic Shock (ReActIF-ICE)

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

MIG Capital leads CHF 7.75 million seed financing for ASTRA Therapeutics

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

Abivax Announces Launch of Public Offering

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis